Attana AB has signed a collaborative research agreement with one of the leading US academic medical centers within biomedical research, focusing on viruses and antibodies. Under the terms of the agreement, Attana will appoint personnel and an Attana CellTM 250 instrument in the United States during Q1. The initial project scope will be performed through mid-June 2022 and can be mutually extended until the end of 2025.

The aim of the collaboration is to jointly identify and develop unique research tools for the R&D of novel vaccines and therapeutic antibodies, based on Attana's technology and expertise. The order will affect Attana's cash flow and earnings in first quarter and second quarter of 2022.